Zoetis (ZTS) Cash & Equivalents (2012 - 2026)
Zoetis (ZTS) posted quarterly Cash & Equivalents of $1.9 billion for Q1 2026, up 12.78% year-over-year from $1.7 billion in Q1 2025, and down 20.78% quarter-over-quarter from $2.4 billion in Q4 2025.
Zoetis (ZTS) Cash & Equivalents (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Cash & Equivalents for 15 consecutive years, with $1.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 12.78% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (up 12.78% YoY), while the FY2025 annual figure was $2.4 billion, up 23.3% from the prior year.
- Cash & Equivalents declined to $1.9 billion in Q1 2026 per ZTS's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $3.6 billion in Q4 2022 and bottomed at $1.4 billion in Q2 2025.
- Historically, Cash & Equivalents has averaged $2.1 billion across 5 years, with a median of $2.0 billion in 2024.
- Annual changes were most pronounced in 2023 — Cash & Equivalents sank 43.0% — and 2025, when it increased 23.3%.
- Zoetis' Cash & Equivalents stood at $3.6 billion in 2022, then tumbled by 43.0% to $2.0 billion in 2023, then retreated by 2.65% to $2.0 billion in 2024, then climbed by 23.3% to $2.4 billion in 2025, then dropped by 20.78% to $1.9 billion in 2026.
- Business Quant data shows ZTS's Cash & Equivalents at $1.9 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.48 Bn |
| Mar 31, 2026 | 1.94 Bn |
| Dec 31, 2025 | 2.45 Bn |
| Sep 30, 2025 | 2.08 Bn |
| Jun 30, 2025 | 1.44 Bn |
| Mar 31, 2025 | 1.72 Bn |
| Dec 31, 2024 | 1.99 Bn |
| Sep 30, 2024 | 1.71 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Mar 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Sep 30, 2023 | 1.75 Bn |
| Jun 30, 2023 | 1.72 Bn |
| Mar 31, 2023 | 2.11 Bn |
| Dec 31, 2022 | 3.58 Bn |
| Sep 30, 2022 | 2.51 Bn |
| Jun 30, 2022 | 2.65 Bn |
| Mar 31, 2022 | 3.14 Bn |
| Dec 31, 2021 | 3.49 Bn |
| Sep 30, 2021 | 3.27 Bn |